Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 13/20 | 0.71 |
| ▸ | BRAF | P15056 | 5/20 | 0.62 |
| ▸ | RAF1 | P04049 | 4/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.56 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.56 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.56 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5897206 | 0.91 | MAPT (0.62) | MAPK14BRAFRAF1MAPTTDP1 | |
| SCHEMBL5897801 | 0.91 | MAPK14 (0.79) | MAPK14BRAFRAF1MAPK13 | |
| SCHEMBL5897136 | 0.86 | MAPK14 (0.75) | MAPK14BRAFRAF1 | |
| SCHEMBL7680447 | 0.86 | MAPK14 (0.69) | MAPK14BRAFRAF1MAPK13HSPB1 | |
| SCHEMBL5897168 | 0.85 | MAPK14 (0.62) | MAPK14BRAFRAF1MAPTMAPK13 | |
| SCHEMBL6967919 | 0.85 | MAPK14 (0.68) | MAPK14BRAFRAF1MAPK13HSPB1 | |
| SCHEMBL16621429 | 0.85 | MAPK14 (0.66) | MAPK14BRAFRAF1MAPK13HSPB1 | |
| SCHEMBL6967922 | 0.84 | MAPK14 (0.65) | MAPK14BRAFRAF1MAPK13HSPB1 | |
| SCHEMBL7678484 | 0.84 | MAPK14 (0.69) | MAPK14BRAFRAF1 | |
| SCHEMBL5897121 | 0.83 | MAPK14 (0.62) | MAPK14BRAFRAF1MAPK13HSPB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7060700-B2 | Amide derivatives useful as inhibitors of the production of cytokines | ASTRAZENECA AB (SE) | 2006-06-13 | — | — | US | disclosed |
| US-20030105142-A1 | Amide derivatives useful as inhibitors of the production of cytokines | ASTRAZENECA AB | 2003-06-05 | — | — | US | disclosed |
| US-6432949-B1 | Amide derivatives useful as inhibitors of the production of cytokines | ASTRAZENECA AB (SE) | 2002-08-13 | — | — | US | disclosed |
| EP-1102750-A1 | AMIDE DERIVATIVES USEFUL AS INHIBITORS OF THE PRODUCTION OF CYTOKINES | AstraZeneca AB (SE) | 2001-05-30 | — | — | EP | disclosed |
| WO-2000007991-A1 | AMIDE DERIVATIVES USEFUL AS INHIBITORS OF THE PRODUCTION OF CYTOKINES | ASTRAZENECA AB (SE) | 2000-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105142-A1 | Amide derivatives useful as inhibitors of the production of cytokines | IL6, IL6ST, IL2 | MAPK14 2563/4885BRAF 1764/4885RAF1 1028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.